Fasken
Fasken is a prominent Canadian law firm with roots dating back to 1862, headquartered in Toronto and operating more than ten offices across Canada, the UK, France, and South Africa. With a team of over 770 lawyers, Fasken provides a wide array of legal services in areas such as competition and marketing, corporate finance, estate planning, government relations, indigenous law, and investment management. The firm serves various sectors, including cannabis, construction, energy, financial services, healthcare, infrastructure, insurance, life sciences, and real estate. Recognized for their expertise, Fasken's lawyers consistently earn accolades from esteemed legal publications, and the firm prides itself on understanding legal issues within the broader context of their clients' business needs. Operating in both English and French, Fasken is committed to being responsive and adaptable to the global challenges faced by their clients. Their success is closely tied to the success of those they represent, reflecting a client-centric approach in their legal practice.
Pro Bono Ontario (PBO) bridges the gap between lawyers who want to donate their services and low-income Ontarians who cannot afford a lawyer or qualify for legal aid.
Asmacure Ltée is a clinical-stage biopharmaceutical company based in Quebec City, Canada, established in 2002. The company specializes in developing proprietary compounds that target cholinergic receptors to treat inflammation, particularly in pulmonary airway diseases. Its lead product, ASM-024, is designed for the treatment of moderate asthma and chronic obstructive pulmonary disease (COPD). This compound features a unique multi-functional mechanism of action, demonstrating anti-inflammatory, bronchoprotective, and smooth muscle relaxation properties in pre-clinical models. ASM-024 has shown promising results in clinical trials, including a phase 2 trial where it exhibited significant improvements in lung function. The compound is formulated as a dry powder for inhalation, which is preferred by many patients for its potential to enhance lung deposition and optimize dosage. Asmacure operates as a subsidiary of Odan Laboratories Ltd. since 2015.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.